Omitting carboplatin could be an efficacious de-escalated neoadjuvant strategy in the presence of dual HER2 blockade for patients with HER2-positive early breast cancer,” said Kun Wang, MD, PhD.

Jazz Pharmaceuticals (($JAZZ)) announced an update on their ongoing clinical study. The clinical study titled A Phase 3, Randomized, Open-label, ...

A stage-four cancer diagnosis once sounded like the end of the road – after all, there is no stage five. When Joe Biden’s ...

DCIS is a non-invasive or pre-invasive breast cancer, meaning the cancer cells are confined to the milk ducts and haven’t ...

Dr. Erika Hamilton discusses the most notable breast cancer treatments currently in development, and how might they change ...

IV infiltration and extravasation remind this cancer patient of the constant challenges of speaking up and advocating for ...

An expert discusses the importance of timely biomarker testing and emerging challenges in treatment sequencing for metastatic ...

Roche’s Itovebi gets European approval to treat people with ER-positive, HER2-negative, advanced breast cancer with a PIK3CA mutation: Basel Thursday, July 24, 2025, 09:00 Hrs [ ...

Circus Extreme is back, featuring breathtaking stunts and aerialist Laura Miller - a breast cancer survivor who has reclaimed ...

Only with the adoption of digital imaging and AI-powered analysis will next-generation precision oncology therapies reach ...

AstraZeneca announces positive results from FLAURA2 phase III trial of Tagrisso plus chemotherapy to treat EGFR-mutated advanced lung cancer: Cambridge, UK Tuesday, July 22, 2025, ...

She credited the same risk assessment test that led to her own diagnosis in 2023 with potentially saving her mother's life.